Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for pancreatic cancer: targeted drug enters final testing phase

NCT ID NCT06625320

Disease control Sponsor: Revolution Medicines, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 trial tests a new drug called daraxonrasib (RMC-6236) against standard treatments for people with metastatic pancreatic cancer that has already been treated. About 500 adults with a specific RAS gene mutation will be randomly assigned to receive either the new drug or standard care. The study measures how long patients live without their cancer growing and overall survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

500 people

The number who actually took part.

Started

Oct 2024

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * At least 18 years old and has provided informed consent. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Histologically or cytologically confirmed PDAC with metastatic disease. * Measurable disease per RECIST 1.1. * Adequate organ function (bone marrow, liver, kidney, coagulation) * Documented RAS mutation status, either mutant or wild-type. RAS mutations defined as nonsynonymous mutations in KRAS, NRAS, or HRAS at codons 12, 13, or 61 (G12, G13, or Q61). * Able to take oral medications. Exclusion Criteria: * Prior therapy with direct RAS-targeted therapy (eg. degraders and/or inhibitors). * History of or known central nervous system metastatic disease. * Any conditions that may affect the ability to take or absorb study treatment * Major surgery within 4 weeks prior to randomization. * Patient is unable or unwilling to comply with protocol-required study visits or procedures

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pancreatic cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm pancreatic adenocarcinoma pancreatic ductal adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pancreatic cancer PDAC Pdac - pancreatic ductal adenocarcinoma

Contacts and locations

Locations

  • Abramson Cancer Center Clinical Research Unit

    Philadelphia, Pennsylvania, 19104, United States

  • Aichi Cancer Center

    Nagoya, 4648681, Japan

  • Azienda Ospedaliera

    Pisa, 56126, Italy

  • Banner MD Anderson Cancer Center

    Gilbert, Arizona, 85234, United States

  • Cancer Care Centers of Brevard Inc

    Palm Bay, Florida, 32909, United States

  • Cancer Institute Hospital of JFCR

    Tokyo, 135-8550, Japan

  • Cedars-Sinai Medical Center

    Los Angeles, California, 90048, United States

  • Centre Eugene Marquis

    Rennes, 35042, France

  • Charité Universitätsmedizin, Campus Berlin Mitte

    Berlin, 13353, Germany

  • City of Hope-Duarte

    Duarte, California, 91010, United States

  • Clinica Universidad de Navarra

    Pamplona, 31008, Spain

  • Columbia University Medical Center

    New York, New York, 10032, United States

  • Dana Farber Cancer Institute

    Boston, Massachusetts, 02215, United States

  • Duke University Medical Center

    Durham, North Carolina, 27710, United States

  • Fondazione IRCCS Istituto Nazionale dei Tumori

    Milan, Italy

  • Fred Hutchinson Cancer Center

    Seattle, Washington, 98109, United States

  • Gustave Roussy

    Villejuif, 94805, France

  • Hopital Paul Brousse

    Villejuif, 94804, France

  • Hospital 12 de Octubre

    Madrid, 28041, Spain

  • Hospital Clinico de Valencia

    Valencia, 46010, Spain

  • Hospital Unversitari

    Barcelona, 08035, Spain

  • Huntsman Cancer Institute

    Salt Lake City, Utah, 84112, United States

  • IEO-Istituto Europeo di Oncologia

    Milan, Italy

  • IOV-Istituto Oncologico

    Padova, 35128, Italy

  • Institut Paoli Calmettes

    Marseille, 13009, France

  • Johns Hopkins

    Baltimore, Maryland, 21287, United States

  • Kanagawa Cancer Center

    Yokohama, 241-8515, Japan

  • Karmanos Cancer Institute

    Detroit, Michigan, 48201, United States

  • MD Anderson Cancer Center

    Houston, Texas, 77030, United States

  • Mayo Clinic Cancer Center - Florida

    Jacksonville, Florida, 32224, United States

  • Mayo Clinic Cancer Center - Phoenix

    Phoenix, Arizona, 85054, United States

  • Mayo Clinic Cancer Center - Rochester

    Rochester, Minnesota, 55905, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10022, United States

  • Mission Hall UCSF

    San Francisco, California, 94158, United States

  • Moffitt Cancer Center

    Tampa, Florida, 33612, United States

  • NYU Lagone Health

    New York, New York, 10016, United States

  • National Cancer Center

    Chiba, 277-8577, Japan

  • National Cancer Center Hospital

    Tokyo, 104-0045, Japan

  • Nationales Centrum fur

    Heidelberg, 69120, Germany

  • Oregon Health and Science University

    Portland, Oregon, 97239, United States

  • Osaka International Cancer

    Osaka, 541-8567, Japan

  • Pan-American Center for Oncology Trials

    San Juan, 00907, Puerto Rico

  • Rocky Mountain Cancer

    Aurora, Colorado, 80012, United States

  • Roswell Park Cancer Institute

    Buffalo, New York, 14263, United States

  • Sarah Cannon Research Institute (Tennessee)

    Nashville, Tennessee, 37203, United States

  • Stephenson Cancer Center

    Oklahoma City, Oklahoma, 73104, United States

  • Texas Oncology - Central South

    Irving, Texas, 75063, United States

  • Texas Oncology Sammons

    Dallas, Texas, 75246, United States

  • The Queen's Medical Center

    Honolulu, Hawaii, 96813, United States

  • The University of Chicago Medical Center

    Chicago, Illinois, 60637, United States

  • UC San Diego Health Moores Cancer Center

    San Diego, California, 92037, United States

  • UCLA

    Los Angeles, California, 90095, United States

  • UPMC Hillman Cancer Center

    Pittsburgh, Pennsylvania, 15232, United States

  • Universitatsklinikum Ulm

    Ulm, 89081, Germany

  • Universitatsklinikum Ulm, Zentru

    München, 81377, Germany

  • University of Cincinnati Medical Center

    Cincinnati, Ohio, 45219, United States

  • University of Miami Sylvester Comprehensive Cancer Center

    Miami, Florida, 33136, United States

  • University of Michigan

    Ann Arbor, Michigan, 48109, United States

  • Virginia Cancer Specialists

    Fairfax, Virginia, 22031, United States

  • Washington University

    St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.